Guggenheim Lowers Structure Therapeutics (GPCR) PT to $90 Ahead of Key Clinical Trial Data

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best small cap stocks with biggest upside potential. On August 7, Guggenheim lowered the firm’s price target on Structure Therapeutics to $90 from $92, while keeping a Buy rating on the shares after the company reiterated that top-line data from the Phase 2b ACCESS and ACCESS II studies for oral small molecule GLP1RA aleniglipron are on track for concurrent year-end 2025 readouts.

As of June 30, the company reported a strong financial position with $786.5 million in cash, cash equivalents, and short-term investments, which are expected to fund operations and key clinical milestones through at least 2027. This includes planned and ongoing clinical trials for the company’s lead candidate, aleniglipron, but excludes future Phase 3 registrational studies.

A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses.

Structure Therapeutics’ oral GLP-1 receptor agonist, called aleniglipron (GSBR-1290), remains on track for key data readouts. Topline 36-week data from the fully enrolled Phase 2b ACCESS (~220 adults) and ACCESS II (~80 adults) studies are expected by the end of 2025. These studies are evaluating doses up to 240 mg with a slow, four-week titration. In addition to these main trials, Structure Therapeutics has expanded the aleniglipron program with three new studies to support its competitive positioning and Phase 3 program design.

Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops and delivers novel oral small-molecule therapeutics to treat various chronic diseases with unmet medical needs in the US.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.